ES2537094T3 - Enterotoxina termolábil de E. coli mutada - Google Patents

Enterotoxina termolábil de E. coli mutada Download PDF

Info

Publication number
ES2537094T3
ES2537094T3 ES07868328.1T ES07868328T ES2537094T3 ES 2537094 T3 ES2537094 T3 ES 2537094T3 ES 07868328 T ES07868328 T ES 07868328T ES 2537094 T3 ES2537094 T3 ES 2537094T3
Authority
ES
Spain
Prior art keywords
coli
thermolabile enterotoxin
seq
subunit
enterotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07868328.1T
Other languages
English (en)
Inventor
Yu-Shen Hsu
Young-Sun Lin
Ta-Tung Yuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Development Center for Biotechnology
Original Assignee
Development Center for Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/779,419 external-priority patent/US8110197B2/en
Application filed by Development Center for Biotechnology filed Critical Development Center for Biotechnology
Application granted granted Critical
Publication of ES2537094T3 publication Critical patent/ES2537094T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/425—Zeins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Botany (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un polipéptido aislado que comprende una subunidad A de enterotoxina termolábil de E. coli, teniendo la subunidad A de enterotoxina termolábil de E. coli una secuencia de aminoácidos seleccionada de un grupo que consiste en los SEQ ID NO: 2, 4, 8, y 10, en donde una enterotoxina termolábil de E. coli que contiene la subunidad A que tiene una secuencia de aminoácidos seleccionada a partir de el grupo que consiste en los SEQ ID NO: 2, 4, 8 y 10 tiene una toxicidad reducida en comparación con una enterotoxina termolábil de E. coli de tipo salvaje que contiene el SEQ ID NO: 5.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
E07868328
18-05-2015
imagen6
Secuencia de aminoácidos (SEQ ID NO: 8) de LTA (S61H)
imagen7
Secuencia de nucleótidos (SEQ ID NO: 9) de LTA(S61Y)
imagen8
Secuencia de aminoácidos (SEQ ID NO: 10) de LTA(S61Y)
imagen9
Para la comparación, también se construyó otro mutante de LT, LTp (S63K), derivado de EWD299 (Dallas et al., 10 1979, J. Bacteriol. 139, 850-859) mediante la sustitución de serina de la posición de aminoácido 63 de la subunidad A por lisina.
Ejemplo 2: Preparación de LT de tipo salvaje y LT que contiene LTA mutada
7
imagen10
imagen11
imagen12

Claims (1)

  1. imagen1
ES07868328.1T 2007-07-18 2007-08-13 Enterotoxina termolábil de E. coli mutada Active ES2537094T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US779419 1991-10-17
US11/779,419 US8110197B2 (en) 2006-10-27 2007-07-18 Mutated E. coli heat-labile enterotoxin
PCT/US2007/075801 WO2009011707A1 (en) 2007-07-18 2007-08-13 Mutated e. coli heat-labile enterotoxin

Publications (1)

Publication Number Publication Date
ES2537094T3 true ES2537094T3 (es) 2015-06-02

Family

ID=40262240

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07868328.1T Active ES2537094T3 (es) 2007-07-18 2007-08-13 Enterotoxina termolábil de E. coli mutada

Country Status (8)

Country Link
EP (1) EP2170377B1 (es)
JP (2) JP5576792B2 (es)
KR (1) KR101699521B1 (es)
CN (1) CN101687026B (es)
BR (1) BRPI0721746B1 (es)
ES (1) ES2537094T3 (es)
RU (1) RU2441879C2 (es)
WO (1) WO2009011707A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8241608B2 (en) * 2010-03-23 2012-08-14 Development Center For Biotechnology Treating allergy with detoxified E. coli heat-labile enterotoxin
ES2550853T3 (es) * 2010-05-03 2015-11-12 Dcb-Usa Llc Conjugación de polisacárido con enterotoxina termolábil (LT) de E. coli desintoxicada usada como vacuna
TWI811673B (zh) * 2020-05-08 2023-08-11 昱厚生技股份有限公司 使用免疫調節劑及包含其之疫苗組合物預防或治療冠狀病毒感染之方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
CA2396871A1 (en) * 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
WO2001070257A1 (en) * 2000-03-17 2001-09-27 Uab Research Foundation Chimeric nontoxic mutants of enterotoxins as mucosal adjuvants for cell-mediated or humoral immunity
WO2004073603A2 (en) * 2003-02-14 2004-09-02 Aeras Global Tuberculosis Vaccine Foundation Dna vaccine that expresses mutant adp-ribosyltransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity
US8110197B2 (en) * 2006-10-27 2012-02-07 Development Center For Biotechnology Mutated E. coli heat-labile enterotoxin

Also Published As

Publication number Publication date
CN101687026B (zh) 2012-07-18
CN101687026A (zh) 2010-03-31
EP2170377A4 (en) 2010-12-29
JP2010533489A (ja) 2010-10-28
KR101699521B1 (ko) 2017-01-24
RU2010105693A (ru) 2011-09-20
JP2014148513A (ja) 2014-08-21
EP2170377B1 (en) 2015-03-04
JP5913406B2 (ja) 2016-04-27
JP5576792B2 (ja) 2014-08-20
RU2441879C2 (ru) 2012-02-10
EP2170377A1 (en) 2010-04-07
WO2009011707A1 (en) 2009-01-22
KR20100054765A (ko) 2010-05-25
BRPI0721746A2 (pt) 2018-10-23
BRPI0721746B1 (pt) 2021-08-31

Similar Documents

Publication Publication Date Title
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
ES2481040T3 (es) Oligonucleótidos inmunoestimulantes
RU2431671C2 (ru) Химерные, гибридные и тандемные полипептиды менингококкового белка nmb1870
CY1125885T1 (el) Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του
ES2558330T3 (es) Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
PE20232039A1 (es) Mutantes de proteina f de rsv
ES2530777T3 (es) Vacunas peptídicas para cánceres que expresan antígenos asociados a tumores
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
AR050095A1 (es) Secuencias de subinidades pequenas de sintasa acetohidroxiacida de monocotiledoneas y metodos de uso.
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
MX2010001856A (es) Proteina.
ES2668967T3 (es) Inmunógenos de Escherichia coli con solubilidad mejorada
PE20140986A1 (es) Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
BR112013010855A2 (pt) luciferases derivadas de oplophorus, novos substratos de coelenterazina e métodos de uso
AR107474A2 (es) Proceso para la preparación de un ácido de 1,2,4-oxadiazol benzoico
MX2011011960A (es) Peptidos penetradores de celulas.
ES2507094T3 (es) Proteína específica del timo
NZ591855A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
PE20110310A1 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas
UA100255C2 (uk) Фармацевтична композиція
ES2537094T3 (es) Enterotoxina termolábil de E. coli mutada
CO6140037A2 (es) Organismos clostridium atenuados recombinados y vacuna
AR075933A1 (es) Composiciones polipeptidas y de inmunizacion conteniendo polipeptidos positivos gram y metodos de uso
AU2016204400A1 (en) Method of inducing an immune response